Wealth Enhancement Advisory Services LLC Sells 3,584 Shares of Aura Biosciences, Inc. $AURA

Wealth Enhancement Advisory Services LLC trimmed its position in Aura Biosciences, Inc. (NASDAQ:AURA) by 23.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,853 shares of the company’s stock after selling 3,584 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Aura Biosciences were worth $78,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Harbor Capital Advisors Inc. increased its position in Aura Biosciences by 27.2% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 32,739 shares of the company’s stock valued at $205,000 after buying an additional 6,998 shares in the last quarter. Acorn Capital Advisors LLC bought a new stake in Aura Biosciences in the 1st quarter valued at about $3,460,000. Ascent Group LLC bought a new stake in Aura Biosciences in the 1st quarter valued at about $124,000. Dynamic Technology Lab Private Ltd acquired a new position in Aura Biosciences during the 1st quarter valued at about $137,000. Finally, Long Focus Capital Management LLC boosted its stake in Aura Biosciences by 30.8% during the 1st quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company’s stock valued at $19,453,000 after purchasing an additional 781,808 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP Amy Elazzouzi sold 7,722 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.70, for a total value of $51,737.40. Following the transaction, the senior vice president owned 86,558 shares in the company, valued at approximately $579,938.60. This represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.30% of the company’s stock.

Aura Biosciences Stock Down 1.8%

Shares of NASDAQ AURA opened at $5.92 on Monday. Aura Biosciences, Inc. has a twelve month low of $4.34 and a twelve month high of $12.38. The stock’s 50 day moving average price is $6.37 and its 200-day moving average price is $6.17. The company has a market capitalization of $367.75 million, a PE ratio of -3.02 and a beta of 0.45.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. As a group, research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AURA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Wednesday, August 13th. Finally, Zacks Research upgraded Aura Biosciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.